Clinical impact of hospitalization on nutritional status in patients admitted in a gastroenterology unit

2018 ◽  
Vol 37 ◽  
pp. S229-S230
Author(s):  
M. Cintoni ◽  
E. Rinninella ◽  
G. Addolorato ◽  
L. Basso ◽  
G. Egidi ◽  
...  
2019 ◽  
Vol 38 ◽  
pp. S173
Author(s):  
J.H. Park ◽  
Y. Ryu ◽  
C.-S. Lim ◽  
Y.C. Shin ◽  
W. Jung ◽  
...  

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
B D Edwards ◽  
R Somayaji ◽  
J Greysson-Wong ◽  
C Izydorczyk ◽  
B Waddell ◽  
...  

Abstract Background Analysis of “emerging” pathogens in cystic fibrosis (CF) lung disease has focused on unique pathogens that are rare in other human diseases or are drug resistant. Escherichia coli is recovered in the sputum of up to 25% of patients with CF, yet little is known about the epidemiology or clinical impact of infection. Methods We studied patients attending a Canadian adult CF clinic who had positive sputum cultures for E coli from 1978 to 2016. Infection was categorized as transient or persistent (≥3 positive sputum cultures, spanning >6 months). Those with persistent infection were matched 2:1 with age, sex, and time-period controls without history of E coli infection, and mixed-effects models were used to assess pulmonary exacerbation (PEx) frequency, lung function decline, hospitalization, and intravenous antibiotic days. Results Forty-five patients (12.3%) had E coli recovered from sputum samples between 1978 and 2016, and 18 patients (40%) developed persistent infection. Nine patients (24%) had PEx at incident infection, and increased bioburden was predictive of exacerbation (P = .03). Risk factors for persistent infection included lower nutritional status (P < .001) and lower lung function (P = .009), but chronic infection with Pseudomonas aeruginosa was protective. There was no difference in annual lung function decline, need for hospitalization or intravenous antibiotics, or risk of PEx in patients with persistent infection. Conclusions Persistent E coli infection was frequent and was more common in CF patients with low nutritional status and lung function. However, this does not predict clinical decline. Multicenter studies would allow better characterization of the epidemiology and clinical impact of E coli infection.


2012 ◽  
Vol 60 (9) ◽  
pp. 1645-1654 ◽  
Author(s):  
Sarah E. Forster ◽  
Hilary J. Powers ◽  
Gemma A. Foulds ◽  
Daniel J. Flower ◽  
Kay Hopkinson ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1560-1560
Author(s):  
Nami Yamashita ◽  
Yuka Inoue ◽  
Kimihiro Tanaka ◽  
Hiroshi Saeki ◽  
Eiji Oki ◽  
...  

1560 Background: Recent reports show that the preoperative immunonutritional status correlate with the survival rate in cancer patients. The Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score are used as screening tools for immunonutritional status and reported to be a predictor of postoperative recurrence in patients with various gastrointestinal cancers. However, the clinical importance of the PNI and CONUT in breast cancer has not been elucidated. The aim of this study is to investigate the clinical impact of preoperative PNI and CONUT on long-term survival of breast cancer patients. Methods: We retrospectively analyzed 653 consecutive stage I-III breast cancer patients who were treated from January 2002 to December 2013. The PNI score was calculated as 10 x serum albumin (g/dl) + 0.005 x total lymphocyte count (per mm3). The CONUT score is calculated from three parameters, serum albumin, cholesterol, and total lymphocytes count. The patients were divided into two groups according to the PNI and CONUT score. The uni- and multivariate Cox regression analyses were performed to evaluate the prognositic value of the PNI and CONUT in breast cancer. Results: The malnutritional status was observed in 170 (26%) and 131 (20%) patients as low-PNI and high-CONUT, respectively. The relapse-free survival (RFS) and overall survival (OS) rates were significantly lower in the low-PNI group (RFS: p < 0.0001, OS: p < 0.0001) and high-CONUT group (RFS: p = 0.0009, OS: p = 0.0018). In the multivariate analysis, low-PNI was independent prognostic factors for both RFS and OS (RFS: HR2.33, p = 0.032, OS: HR5.01, p = 0.0009). In the subset analysis, the low-PNI group showed poor prognosis especially in the postmenopausal, hormone receptor negative patients. The low-PNI also had poorer prognosis in post-recurrence survival. Conclusions: The preoperative PNI is a strong independent predictor of long-term survival among breast cancer patients.


2020 ◽  
Vol 24 (10) ◽  
pp. 1073-1079
Author(s):  
Sophie Allepaerts ◽  
F. Buckinx ◽  
O. Bruyère ◽  
J. Y. Reginster ◽  
N. Paquot ◽  
...  

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3532-3532
Author(s):  
Reinhard Stauder ◽  
Julia Augschoell ◽  
Marije E Hamaker ◽  
Karin A Koinig

Abstract Intro Malnutrition represents a frequent problem in cancer patients. However, data on the prevalence and the clinical impact of malnutrition in older patients with hematological malignancies are so far rare. Objectives Objective of this study was to investigate prospectively the nutritional status at baseline in older patients with blood cancer and to analyze the impact of malnutrition on clinical performance and outcome. Goal was to form a rational basis for interventions and practice guidelines in this continuously growing group of patients. Methods In 149 newly diagnosed patients with a hematological malignancy aged ≥ 70 years from the Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, different nutritional parameters including loss of appetite, recent weight loss, Mini Nutritional Assessment (MNA), body mass index, serum albumin and the inflammation marker C-reactive protein (CRP) were assessed and compared with status in multidimensional geriatric assessment and with overall survival (OS). SPSS (IBM Corporation, Armonk, NY, USA) was used for all statistical analyses. Two-year overall survival was analyzed with Kaplan-Meier methods and the log rank test. Hazard ratios were first analyzed in a univariate Cox proportional hazard regression. Parameters statistically significant in the univariate analyses were then included in the multivariate Cox regressions, additionally assessing the significance of the parameters with a bootstrapped model. Canoco 5.10 was used for principal component analyses (PCA). Results A moderate or severe decrease of appetite was reported by 23 % and 40% of patients. Moreover, a recent weight loss of 1-3 or >3kg was present in 19 and 31% and a BMI <23kg/m2 was found in 29% of patients. Based on MNA-evaluation, 44% revealed a risk of malnutrition and 14% of manifest malnutrition. Prevalence of lowered serum albumin <3.5 g/dL was detected in 14% of patients. Geriatric impairments >3 were detected in about one third of the patients (36%). PCA demonstrated clustering of impairments in performance status and in IADL as well as of low appetite, low serum albumin, fatigue and depression in the first principal component accounting for a variability of 24%. Loss of appetite, recent weight loss, impaired MNA, low serum albumin and elevated CRP were significantly associated with shortened OS. Recent weight loss >3kg and low BMI remained significant predictive parameters for OS in a Cox regression analysis (HR: 2.01 (1.19-3.38), p=0.009 and HR: 2.46 (1.53-3.96), p<0.001, respectively). Conclusion These analyses reveal malnutrition at initial diagnosis in a relevant proportion of older patients with a hematological malignancy. Importantly, impaired nutritional status is associated with shortened overall survival. The correlation between malnutrition, fatigue, impaired performance and functional capacities, and inflammation might suggest an underlying common pathway. Thus, assessment of nutritional status is essential in studies and in daily practice and forms the basis for interventions to improve nutritional status. More robust data on the clinical impact of malnutrition in hematological malignancies and the effect of geriatric interventions on essential oncologic and non-oncologic outcomes such as survival and quality of life are needed. Disclosures Stauder: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Teva: Research Funding.


Sign in / Sign up

Export Citation Format

Share Document